ClinicalTrials.gg
CompletedNCT06566768Updated Jul 2, 2025

Study to Evaluate Drug Levels of Various Solid Gastro-retentive Formulations of Deucravacitinib (BMS-986165) in Healthy Participants

A Phase 1 interventional study of Deucravacitinib in Healthy Participants, sponsored by Bristol-Myers Squibb. Completed at 1 site in United Kingdom. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-02.

Sponsored by Bristol-Myers Squibb · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2025, 1 year 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
52
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Study summary

The purpose of this study is to identify drug levels of gastro-retentive (GR) formulations which prolong retaining time in the stomach of deucravacitinib (BMS-986165) in Healthy Participants.

02

Conditions studied

  • Healthy Participants

Keywords

  • Deucravacitinib
  • BMS-986165
  • Healthy volunteers
  • Single-dose
03

In context

Lead sponsor

Bristol-Myers Squibb is the lead sponsor of 1,561 studies on the registry; 118 are open to participants now.

Of its 436 completed or terminated interventional studies of FDA-regulated products, 228 (52%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy males and healthy females according to the assessment of the Investigator.
  • of 18.0 kg/m\^2 through 32.0 kg/m\^2, inclusive, and body weight ≥ 50 kg.

Exclusion criteria

Exclusion Criteria:

  • Any significant acute or chronic medical illness.
  • Current or recent (within 3 months of first dose) gastrointestinal (GI) disease that could possibly affect drug absorption, distribution, metabolism, and excretion.
  • History of any significant drug allergy.
  • Other protocol-defined Inclusion/Exclusion criteria apply.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
52 participants (actual)

Study arms

  • Experimental
    Part A: Deucravacitinib

    Drug: Deucravacitinib

  • Experimental
    Part B: Deucravacitinib

    Drug: Deucravacitinib

Interventions

  • Specified dose on specified days

    Also known as: BMS-986165

06

What researchers measure

Primary outcomes

  1. Maximum observed plasma concentration (Cmax)

    Time frame: Up to approximately 5 days

  2. Concentration at 24 hours post dose (C24)

    Time frame: Up to approximately 5 days

  3. Area under the concentration-time curve from time zero to time of last quantifiable concentration [AUC(0-T)]

    Time frame: Up to approximately 5 days

Secondary outcomes

  1. Incidence of adverse events (AEs)

    Time frame: Up to approximately 1 month

  2. Incidence of serious adverse events (SAEs)

    Time frame: Up to approximately 1 month

  3. Incidence of AEs leading to discontinuation

    Time frame: Up to approximately 1 month

  4. Incidence of participants with vital sign abnormalities

    Time frame: Up to approximately 1 month

  5. Incidence of participants with electrocardiogram (ECG) abnormalities

    Time frame: Up to approximately 1 month

  6. Incidence of participants with physical examinations abnormalities

    Time frame: Up to approximately 1 month

  7. Incidence of participants with clinical laboratory abnormalities

    Time frame: Up to approximately 1 month

  8. Time of maximum observed concentration (Tmax)

    Time frame: Up to approximately 5 days

  9. Apparent terminal plasma half-life (T-HALF)

    Time frame: Up to approximately 5 days

  10. Apparent total body clearance (CLT/F)

    Time frame: Up to approximately 5 days

07

Study locations

1 site
  • Local Institution - 0001
    Nottingham, Nottinghamshire NG11 6JS, United Kingdom
08

References and documents

Individual participant data

Plan to share: No — BMS will provide access to individual anonymized participant data upon request from qualified researchers, and subject to certain criteria. Additional information regarding Bristol Myer Squibb's data sharing policy and process can be found at: https://www.bms.com/researchers-and-partners/clinical-trials-and research/disclosurecommitment.html

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in Jun 2025, 8 months.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 21, 2024
First posted
Aug 22, 2024
StartActual
Oct 7, 2024
Primary completionActual
Jun 13, 2025
CompletionActual
Jun 13, 2025
Last update
Jul 2, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 2, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06566768
Responsible party
Sponsor
First posted
Aug 22, 2024
Start date
Oct 7, 2024
Primary completion
Jun 13, 2025
Completion
Jun 13, 2025
Last update
Jul 2, 2025

Study contacts

Bristol-Myers Squibb
study director · Bristol-Myers Squibb

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Deucravacitinib

Start the discussion